Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

193.81 -0.31 (-0.16%)
Streaming Delayed Price Updated: 12:07 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 338,914
Open 193.34
Bid (Size) 193.72 (2)
Ask (Size) 193.89 (3)
Prev. Close 194.11
Today's Range 193.34 - 195.86
52wk Range 189.44 - 319.76
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
Where Biogen Stands With Analysts
Via Benzinga

Performance

YTD
-27.61%
-27.61%
1 Month
-10.56%
-10.56%
3 Month
-21.95%
-21.95%
6 Month
-23.52%
-23.52%
1 Year
-33.86%
-33.86%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
Via Talk Markets
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Forecasting The Future: 18 Analyst Projections For Biogen
Via Benzinga
A Closer Look at 21 Analyst Recommendations For Biogen
Via Benzinga
Tuesday Talk: Big-Tech Under Attack
Via Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Via Benzinga
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Via Talk Markets
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
Via Benzinga
Topics Economy
Exposures Interest Rates
Are These 5 Undervalued Stocks Ready to Break Out?
Via MarketBeat
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
Via Benzinga
Exposures Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
Via Investor's Business Daily
Exposures Product Safety
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Via Benzinga
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Via InvestorPlace
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.